Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro

Calcified Tissue International

Volumn 72, Issue 2, 2003, Pages 143-150

  Still, K ^a   Phipps, R J ^b   Scutt, A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Bisphosphonate; BMSC; CFU f; Geranylgeraniol; Osteoblast

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; ETIDRONIC ACID; EU 5631; FARNESOL; GERANYLGERANIOL; MEVALONIC ACID; NE 10503; RISEDRONIC ACID;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; FIBROBLAST; IN VITRO STUDY; MALE; NONHUMAN; OSSIFICATION; OSTEOPOROSIS; PRIORITY JOURNAL; RAT; STROMA CELL;

ALENDRONATE; ANIMALS; BONE AND BONES; BONE MARROW CELLS; CELL SURVIVAL; DIPHOSPHONATES; DITERPENES; ETIDRONIC ACID; FARNESOL; FIBROBLASTS; MODELS, ANIMAL; RATS; RATS, WISTAR; STROMAL CELLS;

EID: 0041766815     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-001-2066-y     Document Type: Article

References (48)

1. Fleisch H (1997) Bisphosphonates in bone disease. From the laboratory to the patient. The Parthenon Publishing Group Inc, New York, NY pp 32-163
2. Papapoulos S (1996) Bisphosphonates. In: Marcus R, Feldman D, Kelsey J (eds) Pharmacology and use in the treatment of osteoporosis. Academic Press, San Diego, CA, pp 1209-1234
3. Rodan GA, Fleisch H (1996) Bisphosphonates: mechanism of action. J Clin Invest 97:2692-2696
4. Hughes DE, MacDonald BR, Russell RGG, Gowen M (1989) Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83:1930-1935
5. Löwik CWGM, van der Pluim G, van der Wee-Pals LJA, Bloys van Treslong de Groot H, Bijvoet OLM (1988) Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res 3:185-192
6. 2MBP-coated bone. Bone Miner 6:33-43
7. Vitte C, Fleisch H, Guenther HL (1996) Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137:2324-2333
8. Hughes DE, Wright KE, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487
9. Lin CL, Moniz C, Chow JW (2000) Treatment with fluoride or bisphosphonates prevents bone loss associated with colitis in the rat. Calcif Tissue Int 67:373-377
10. Hunziker J, Wronski TJ, Miller SC (2000) Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. J Dent Res 79:1431-1438
11. Kodama Y, Nakayama K, Fuse H, Fukumoto S, Kawahara H, Takahashi H, Kurokawa T, Sekiguchi C, Nakamura T, Matsumoto T (1997) Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats. J Bone Miner Res 12:1058-1067
12. Marc J, Prezelj J, Komel R, Kocijancic A (1999) VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporos Int 10:303-306
13. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB (1998) Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431-1438
14. Tobias JH, Laversuch CJ, Chambers TJ, Gallagher AC (1996) Aminohexane bisphosphonate suppresses bone turnover in postmenopausal women more rapidly than oestrogen-gestagen therapy. Br J Rheumatol 35:636-641
15. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363-1374
16. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480
17. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA (1993) The effects of 2-year treatment with the amino-bisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovarectomized nonhuman primates. J Clin Invest 92:2577-2586
18. Storm T, Steiniche T, Thamsborg G, Melsen F (1993) Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 8:199-208
19. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G (1998) Bisphosphonates stimulate formatin of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 22:455-461
20. Maniatopoulos C, Sodek J, Melcher AH (1998) Bone formation in vitro by stromal cells obtained from bone marrow of young rats. Cell Tissue Res 254:317-330
21. Bellows CG, Ishida H, Aubin JE, Heersche JN (1990) Parathyroid hormone reversibly suppresses the differentiation of osteoprogenitor cells into functional osteoblasts. Endocrinol 127:3111-3116
22. 3-induced inhibition of bone nodule formation in long-term cultures of fetal rat calvaria cells. Endocrinology 132:61-66
23. 2 on bone: induction of a transition from non-adherent to adherent osteoblast precursors. J Bone Miner Res 10:474-489
24. 2 induces the transition from non-adherent to adherent bone marrow mesenchymal precursor cells via a cAMP/EP mediated mechanism. Prostaglandins 49:383-395
25. 2 in the recruitment of bone marrow mesenchymal precursor cells to the osteoblastic lineage: positive and negative effects. Calcif Tissue Int 59:154-162
26. Dobson KR, Reading L, Haberey M, Marine X, Scutt A (1999) Centrifugal isolation of bone marrow from bone: an improved method for the recovery and quantitation of bone marrow osteoprogenitor cells from rat tibiae and femurae. Calcif Tissue Int 65:411-413
27. Bancroft DJ, Stevens A (1982) Theory and practice of histological techniques, 2nd ed., Churchill Livingstone, NY
28. Dobson K, Reading L, Scutt A (1999) A cost-effective method for the automatic quantitative analysis of fibroblastic colony-forming units with osteoblastic potential. Calcif Tissue Int 65:166-172
29. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including RAS. J Bone Miner Res 13:581-589
30. Benford HL, Frith JC, Auriola S, Mönkkönen J, Rogers MJ (1999) Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct classes of bisphosphonate drugs. Mol Pharmacol 56:131-140
31. Erben RG, Scutt AM, Miao D, Kollenkirchen U, Haberey M (1997) Short-term treatment of rats with high-dose calcitriol stimulates bone formation in vivo and increases the number of osteoblast precursor cells in the bone marrow. Endocrinology 138:4629-4635
32. Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba Y, Uchiyama Y, Suda T, Yoshiki S, Takahashi HE (1994) Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in the bone marrow. Bone 15:717-723
33. 2 in young rats increases the osteogenic capacity of bone marrow. Bone 20:521-526
34. Mackie PS, Fisher JL, Zhou H, Choong PF (2001) Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 84:951-958
35. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC (2000) Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60:6001-6007
36. Evans CE, Braidman IP (1994) Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner 26:95-107
37. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen (2001) The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 12:459-465
38. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes PJ, Masarachia PJ, Wesolowski G, Russell RGG, Rodan AA, Reszka AA (1999) Alendronate mechanism of action: geranlylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activtion in vitro. Proc Natl Acad Sci USA 96:133-138
39. Keller RK, Fliesler SJ (1999) Mechanism of action of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway. Biochem Biophys Res Comm 266:560-563
40. Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MJ (1998) Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 13:1668-1678
41. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G (2000) Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373:231-241
42. Friedenstein AJ, Latzink NV, Gorskaya YuF, Luria EA, Moskvina IL (1992) Bone marrow stromal colony formation requires stimulation by haemopoietic cells. Bone Min 18:199-213
43. Cecchini MG, Fleisch H (1990) Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res 5:1019-1027
44. Berkhout TA, Simon HM, Patel DD, Bentzen C, Niesor E, Jackson B, Suckling KE (1996) The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutarylcoenzyme A reductase. J Biol Chem 271:14376-14382
45. Flach J, Antoni I, Villemin P, Bentzen CL, Niesor EJ (2000) The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol. Biochem Biophys Res Commun 270:240-246
46. Kawabe Y, Suzuki T, Hayashi M, Hamakubo T, Sato R, Kodama T (1999) The physiological role of sterol regulatory element-binding protein-2 in cultured human cells. Biochim Biophys Acta 1436:307-318
47. Repa JJ, Mangelsdorf DJ (2000) The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 16:459-481
48. Hoffman A, Stepensky D, Ezra A, Van Gelder JM, Golomb G (2001) Mode of administration-dependant pharmacokinetics of bisphosphonates and bioavailability determination. Int J Pharmaceut 220:1-11